Ameliorative effects of Ellagic acid against toxicity of cisplatin in male rats

Abstract

Cisplatin (Cis) is a regularly used medicine to treat cancer, particularly breast cancer, however it has adverse effects that impact other bodily systems. The goal of this study is to employ Ellagic acid (Ell) to reduce the drug's side effects. A total of forty male albino rats are randomly allocated into four groups: Control, Cis, Cis+Ell, and Ell acid. Serum lipid profile and sexual hormones (FSH, LH, and testosterone) were measured biochemically, and liver slices from all groups were processed for histological analysis. Our findings demonstrated that following Cis administration, Ell treatment resulted in significant improvements in all biochemical parameters, with Ell causing considerable reductions in cholesterol, triglycerides, and LDL while increasing HDL levels. Ell induced a considerable increase in the concentrations of FSH, LH, and testosterone in the Cis+Ell group, despite Cis dramatically lowering these levels in the second group. Ell can promote a great recovery in the hepatic architecture following a Cis-induced deformation, according to histopathological analysis. Finally, Ell therapy can help to mitigate the harmful effects of Cis delivery.